Грани проблемы инфильтративного эндометриоза: от патогенеза к эффективной терапии

1. Ruffo G, Scopelliti F, Manzoni A, et al. Long-term outcome after laparoscopic bowel resections for deep infiltrating endometriosis: a single-center experience after 900 cases. Biomed Res Int. 2014; 2014: 463058. DOI: 10.1155/2014/463058/
2. Matalliotakis IM, Cakmak H, Fragouli YG, et al. Epidemiological characteristics in women with and without endometriosis in the Yale series. Arch Gynecol Obstet. 2007; 277: 389–93.
3. Marcellin L, Santulli P, Pinzauti S, et al. Age at menarche does not correlate with the endometriosis phenotype. PLoS ONE. 2019; 14 (7): e0219497. DOI: 10.1371/journal.pone.0219497)
4. Vannuccini S, Lazzeri L, Orlandini C, et al. Potential influence of in utero and early neonatal exposures on the later development of endometriosis. Fertil Steril. 2016; 105: 997–1002.
5. Borghese B, Sibiude J, Santulli P, et al. Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case-control study. PLoS One. 2015; 10e0117387.
6. Vitonis AF, Baer HJ, Hankinson SE, et al. A prospective study of body size during childhood and early adulthood and the incidence of endometriosis. Hum Reprod. 2010; 25 (5): 1325–34. DOI: 10.1093/humrep/deq039
7. Ottolina J, Schimberni M, Makieva S, et al. Early-life factors, in-utero exposures and endometriosis risk: a meta-analysis. Reprod Biomed Online. 2020. DOI: 10.1016/j.rbmo.2020.04.005
8. Shafrir AL, Farland LV, Shah DK, et al. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol. 2018; 51: 1–15. DOI: 10.1016/j.bpobgyn.2018.06.001
9. Farland Leslie V, Eliassen A Heather, Tamimi Rulla M, et al. History of breast feeding and risk of incident endometriosis: prospective cohort study. BMJ. 2017; 358: j3778.
10. Xie J, Kvaskoff M, Li Y, et al. Severe teenage acne and risk of endometriosis. Hum Reprod. 2014; 29 (11): 2592–9. DOI: 10.1093/humrep/deu207
11. Vercellini P, Buggio L, Somigliana E, et al. ‘Behind blue eyes’: the association between eye colour and deep infiltrating endometriosis. Hum Reprod. 2014; 29 (10): 2171–5. DOI: 10.1093/humrep/deu169
12. Missmer SA, Spiegelman D, Hankinson SE, et al. Natural hair color and the incidence of endometriosis. Fertil Steril. 2006; 85: 866–70.
13. Гинекология. Национальное руководство. Под ред. Г.М. Савельевой, Г.Т. Сухих, В.Н. Серова и др. М.: ГЭОТАР-Медиа, 2017 [Gynecology. National leadership. Ed. G.M. Savelyeva, G.T. Sukhikh, V.N. Serova et al. Moscow: GEOTAR-Media, 2017 (in Russian)].
14. Koninckx PR, Ussia A, Adamyan L, et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019; 111 (2): 327–40. 
DOI: 10.1016/j.fertnstert.2018.10.013
15. Sampson JA. Metastatic or embolic endometriosis due to menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927; 3 (2): 93–110.
16. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927; 14 (2): 422–69.
17. Locci R, Nisolle M, Angioni S, et al. Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis. Reprod Biol Endocrinol. 2013; 11: 94. DOI: 10.1186/1477-7827-11-94
18. Cazacu E, Zota E, Margaritescu C, et al. Immunoexpression of matrix metalloproteinases MMP-1, MMP-2, MMP-9 and MMP-14 in extragenital endometriosis and eutopic endometrium. Mold Med J. 2020; 63 (4): 6–11. DOI: 10.5281/zenodo.4016800
19. Ζafrakas M, Κοtronis Κ, Papasozomenou P, et al. Extracellular matrix metalloproteinases in the etiopathogenesis of endometriosis: a systematic review and critical appraisal. Clin Exp Obstet Gynecol. 2020; 47 (2): 147–53.
20. Huang Y, Shen L, Cai A, Xiao J. Effect of warming Yang and removing blood stasis method on matrix metalloproteinases/tissue inhibitor metalloproteinases levels secreted by cultured endometrial cells from patients with endometriosis. J Tradit Chin Med. 2015; 35 (5): 571–6.
21. Lessey BA, Castelbaum AJ, Sawin SW, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metabol. 1994; 79: 643–9.
22. Shaco-Levy R, Sharabi S, Benharroch D, et al. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Eur J Obstet Gynecol Reprod Biol. 2008; 139: 226–32.
23. Matsuzaki S, Darcha C: Involvement of the Wnt/beta-catenin signaling pathway in the cellular and molecular mechanisms of fibrosis in endometriosis. PLoS One. 2013; 8:e76808.
24. Мнихович М.В., Кактурский Л.В., Безуглова Т.В., и др. Сравнительная иммуногистохимическая оценка экспрессии Е-кадгерина и β-катенина при метастатическом и неметастатическом раке молочной железы неспецифического типа. Опухоли женской репродуктивной системы. 2018; 14 (2): 14–20 [Mnikhovich MV, Kakturskii  LV, Bezuglova TV, et al. Sravnitel’naia immunogistokhimicheskaia otsenka ekspressii E-kadgerina i β-katenina pri metastaticheskom i nemetastaticheskom rake molochnoi zhelezy nespetsificheskogo tipa. Opukholi zhenskoi reproduktivnoi sistemy. 2018; 14 (2): 14–20 (in Russian)].
25. Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002; 17 (10): 2715–24. DOI: 10.1093/humrep/17.10.2715
26. Ефанова Н.А., Михельсон А.Ф., Лебеденко Е.Ю., и др. Современные аспекты патогенеза основных клинических проявлений и перспектив терапии эндометриоза. Таврический медико-биологический вестник. 2018; 21 (3) [Efanova NA, Mikhel’son AF, Lebedenko EIu, et al. Sovremennye aspekty patogeneza osnovnykh klinicheskikh proiavlenii i perspektiv terapii endometrioza. Tavricheskii mediko-biologicheskii vestnik. 2018; 21 (3) (in Russian)].
27. Schulke L, Berbic M, Manconi F, et al. Dendritic cell populations in the eutopic and ectopic endometrium of women with endometriosis. Hum Reprod. 2009; 24 (7): 1695–703. DOI: 10.1093/humrep/dep071
28. Koninckx PR, Ussia A, Tahlak M, et al. Infection as a potential cofactor in the genetic-epigenetic pathophysiology of endometriosis: a systematic review. Facts Views Vis Obgyn. 2019; 11 (3): 209–16.
29. Hazzard TM, Molskness TA, Chaffin CL, Stouffer RL. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval. Mol Hum Reprod. 1999; 5: 1115–21.
30. Bourlev V, Volkov N, Pavlovitch S, et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006; 132: 501–9.
31. Оразов М.Р., Токтар Л.Р. Бактериальная контаминация: новое слово в патогенезе эндометриоза. Акушерство и гинекология. 2018; 
3 (21). Режим доступа: https://cyberleninka.ru/article/n/bakterialnaya-kontaminatsiya-novoe-slovo-v-patogeneze-endometrioza. Ссылка активна на 22.12.2020 [Orazov MR, Toktar LR. Bakterial’naia kontaminatsiia: novoe slovo v patogeneze endometrioza. Akusherstvo i ginekologiia. 2018; 3 (21). Available at: 
https://cyberleninka.ru/article/n/bakterialnaya-kontaminatsiya-novoe-slovo-v-patogeneze-endometrioza. Accessed: 22.12.2020 (in Russian)].
32. Короткова Т.Д., Адамян Л.В., Степанян А.А., и др. Клеточные и молекулярные факторы врожденного иммунитета в патогенезе наружного генитального эндометриоза у женщин. Проблемы репродукции. 2018; 
24 (6): 22–31 [Korotkova TD, Adamian LV, Stepanian AA, et al. Kletochnye i molekuliarnye faktory vrozhdennogo immuniteta v patogeneze naruzhnogo genital’nogo endometrioza u zhenshchin. Problemy reproduktsii. 2018; 24 (6): 22–31 (in Russian)]. DOI: 10.17116/repro20182406122 
33. Kalinitchenko SY. Vitamin D and women’s reproductive health. Problemi reprodukcii. 2016; 4: 28–36.
34. Evangelisti G, Barra F, Fichera M, Ferrero S. Vitamin D and endometriosis: Is there a correlation with disease severity? Clin Exp Reprod Med. 2020; 47 (3): 233–4. DOI: 10.5653/cerm.2019.03342
35. Оразов М.Р., Радзинский В.Е., Хамошина М.Б., и др. Витамин D3 (холекальциферол) и тазовая боль, индуцированная эндометриозом яичников. Трудный пациент. 2018; 16 (4): 34–9 [Orazov MR, Radzinskii VE, Khamoshina MB, et al. Vitamin D3 (kholekal’tsiferol) i tazovaia bol’, indutsirovannaia endometriozom iaichnikov. Trudnyi patsient. 2018; 16 (4): 34–9 (in Russian)].
36. Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil Steril 2017; 108 (6): 872–85.e1. DOI: 10.1016/j.fertnstert.2017.08.036
37. Pacchiarotti A, Caserta D, Sbracia M, Moscarini M. Expression of oct-4 and c-kit antigens in endometriosis. Fertil Steril. 2011; 95 (3): 1171–3. DOI: 10.1016/j.fertnstert.2010.10.029
38. Toullec L, Batteux F, Santulli P, et al. High Levels of Anti-GM-CSF Antibodies in Deep Infiltrating Endometriosis. Reprod Sci. 2020; 27 (1): 211–7. DOI: 10.1007/s43032-019-00021-8
39. Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril. 1991; 55 (4): 759–65.
40. Chapron C, Fauconnier A, Vieira M, et al. Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. Hum Reprod. 2003; 18 (1): 157–61.
41. Hoo W-L, Hardcastle R, Louden K. Management of endometriosis-related pelvic pain. Obstet Gynaecol. 2017; 19: 131–8. DOI: 10.1111/tog.12375
42. Vercellini P, Fedele G, Aimi G, et al. Association between endometriosis stage, lesion type, patient char-acteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod. 2007; 22 (1): 266–71.
43. Endometriosis: science and practice. Edited by L.C. Giudice, J.L.H. Evers, D.L. Healy. Blackwell Publishing Ltd, 2012; p. 82–3.
44. Carmignani L, Vercellini P, Spinelli M, et al. Pelvic endometriosis and hydroureteronephrosis. Fertil Steril. 2010; 93: 1741–4.
45. American Society for Reproductive Medicine. Endometriosis and infertility: A committee opinion. Fertil Steril. 2012; 98: 591–8.
46. Баринов С.В., Лазарева О.В., Игнатьев Ю.Т., и др. Актуальные вопросы диагностики глубокого инфильтративного эндометриоза.Мать и Дитя в Кузбассе. 2020; 1 (80): 10–7 [Barinov SV, Lazareva OV, Ignat’ev IuT, et al. Aktual’nye voprosy diagnostiki glubokogo infil’trativnogo endometrioza. Mat’ i Ditia v Kuzbasse. 2020; 1 (80): 10–7  (in Russian)]. DOI: 10.24411/2686-7338-2020-10003
47. Chapron C, Lang JH, Leng JH, et al. Factors and regional differences associated with endometriosis: a multi-country, casecontrol study. Adv Ther. 2016; 33: 1385–407. DOI: 10.1007/s12325-016-0366-x
48. Matalliotakis I, Panidis D, Vlassis G, et al. Unexpected increase of the CA–19-9 tumor marker in patients with endometriosis. Eur J Gynaecol Oncol. 1998; 9: 498–500.
49. Fiala L, Bob P, Raboch J. Oncological markers CA–125, CA–19-9 and endometriosis. Medicine (Baltimore). 2018; 97 (51): 13759.
50. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016; 4 (4): CD012165. DOI: 10.1002/14651858.CD012165
51. Alborzi S, Rasekhi A, Shomali Z, et al. Diagnostic accuracy of magnetic resonance imaging, transvaginal, and transrectal ultrasonographyin deep infiltrating endometriosis. Medicine (Baltimore). 2018; 97 (8): e9536. DOI: 10.1097/MD.0000000000009536
52. Zannoni L, Del Forno S, Coppola F, et al. Comparison of transvaginal sonography and computed tomography-colonography with contrast media and urographic phase for diagnosing deep infiltrating endometriosis of the posterior compartment of the pelvis: a pilot study. Jpn J Radiol. 2017; 35 (9): 546–54. DOI: 10.1007/s11604-017-0665-4
53. Chapron C, Vieira M, Chopin N, et al. Accuracy of rectal endoscopic ultrasonography and magnetic reso-nance imaging in the diagnosis of rectal involvement for patients presenting with deeply infiltrating endometriosis. J Ultrasound Obstet Gynecol. 2004; 24: 175–9.
54. Siegelman ES, Oliver ER. MR Imaging of Endometriosis: Ten Imaging Pearls. RadioGraphics. 2012; 32 (6): 1675–91.
55. Grasso RF, Di Giacomo V, Sedati P, et al. Diagnosis of deep infiltrating endometriosis: accuracy of magnetic resonance imaging and transvaginal 3D ultrasonography. Abdom Imaging. 2009; 19: 314.
56. Anaf V, El Nakadi I, De Moor V, et al. Anatomic significance of a positive barium enema in deep infiltrating endometriosis of the large bowel. World J Surg. 2009; 33: 822–7.
57. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005; 20 (10): 2698–704.
58. Клинические рекомендации. Эндометриоз. Минздрав России, 2020 [Klinicheskie rekomendatsii. Endometrioz. Minzdrav Rossii, 2020 (in Russian)].
59. Sirintawat N, Sawang K, Chaiyasamut T, Wongsirichat N. Pain measurement in oral and maxillofacial surgery. J Dent Anesth Pain Med. 2017; 17 (4): 253–63. DOI: 10.17245/jdapm.2017.17.4.253
60. Невропатическая боль: клинические рекомендации по диагностике и лечению Российского общества по изучению боли. Клинические рекомендации №4. 2018 [Nevropaticheskaia bol’: klinicheskie rekomendatsii po diagnostike i lecheniiu Rossiiskogo obshchestva po izucheniiu boli. Klinicheskie rekomendatsii №4. 2018  (in Russian)]. 
DOI: 10.25731/RASP.2018.04.025
61. Lai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in Endometriosis. Int J Biol Sci. 2019; 15 (13): 2783–97. DOI: 10.7150/ijbs.35128
62. Кузнецова Д.Е., Прокопенко С.В., Макаренко Т.А., и др. Дифференцированная терапия инфильтративного эндометриоза и синдрома хронической тазовой боли в зависимости от вегетативного статуса пациенток. Проблемы репродукции. 2018; 24 (6): 121–31 [Kuznetsova DE, Prokopenko SV, Makarenko TA, et al. Differentsirovannaia terapiia infil’trativnogo endometrioza i sindroma khronicheskoi tazovoi boli v zavisimosti ot vegetativnogo statusa patsientok. Problemy reproduktsii. 2018; 24 (6): 121–31 (in Russian)]. DOI: 10.17116/repro201824061121 
63. Слободин Т.Н., Маслова И.Г. Патогенез и современный комплексный подход в лечении болевых синдромов в неврологии. Междунар. неврол. журн. 2018; 6 (100). Режим доступа: https://cyberleninka.ru/article/n/patogenez-i-sovremennyy-kompleksnyy-podhod-v-lechenii-bolevyh-sind.... Ссылка активна на 07.01.2021 [Slobodin TN, Maslova IG. Patogenez i sovremennyi kompleksnyi podkhod v lechenii bolevykh sindromov v nevrologii. Mezhdunar. nevrol. zhurn. 2018; 6 (100). Available at: https://cyberleninka.ru/article/n/patogenez-i-sovremennyy-kompleksnyy-podhod-v-lechenii-bolevyh-sind.... Accessed: 07.01.2021 (in Russian)].
64. Aoki KR. Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A. Neurotoxicology. 2005; 26: 785–93. DOI: 10.1016/j.neuro.2005.01.017
65. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting: A review of the literature. Pain Practice. 2008; 8: 269–76. DOI: 10.1111/j.1533-2500.2008.00202.x
66. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004; 107: 125–33. DOI: 10.1016/j.pain.2003.10.008
67. Tandon HK, Stratton P, Sinaii N, et al. Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a painfocused treatment. Regional Anesthesia Pain Med. 2019; 44: 886–92. DOI: 10.1136/rapm-2019-100529
68. Del Forno S, Mabrouk M, Arena A, et al. Dienogest or norethindrone acetate for the treatment of ovarian endometriomas: can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019; 238: 120–4.
69. Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J Pain Res. 2019; 12: 2371–8.
70. Bayer. Visanne Post-approval Observational Study (VIPOS) [cited 2019 Nov]. Available at: https://clinicaltrials.bayer.com/study/20018
71. Bayer. To evaluate effectiveness of Visanne in improving quality of life in Asian women with Endometriosis [cited 2019 Nov]. Available at: https://clinicaltrials.bayer.com/study/2084
72. Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2mg dienogest/30 microg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 39 (8): 923–31.
73. Yamanaka A, Hada T, Matsumoto T, et al. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017; 216: 51–5.
74. Ebert AD, Dong L, Merz M, et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: The VISanne Study to Assess Safety in ADOlescents. J Pediatr Adolesc Gynecol. 2017; 30 (5): 560–7.
75. Seracchioli R, Mabrouk M, Manuzzi L, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom recurrence after conservative surgery for endometriosis. Hum Reprod. 2009; 24 (11): 2729–352.
76. Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008; 90 (5): 1583–8.
77. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015; 292 (3): 523–9.
DOI: 10.1007/s00404-015-3681-6

________________________________________________

1. Ruffo G, Scopelliti F, Manzoni A, et al. Long-term outcome after laparoscopic bowel resections for deep infiltrating endometriosis: a single-center experience after 900 cases. Biomed Res Int. 2014; 2014: 463058. DOI: 10.1155/2014/463058/
2. Matalliotakis IM, Cakmak H, Fragouli YG, et al. Epidemiological characteristics in women with and without endometriosis in the Yale series. Arch Gynecol Obstet. 2007; 277: 389–93.
3. Marcellin L, Santulli P, Pinzauti S, et al. Age at menarche does not correlate with the endometriosis phenotype. PLoS ONE. 2019; 14 (7): e0219497. DOI: 10.1371/journal.pone.0219497)
4. Vannuccini S, Lazzeri L, Orlandini C, et al. Potential influence of in utero and early neonatal exposures on the later development of endometriosis. Fertil Steril. 2016; 105: 997–1002.
5. Borghese B, Sibiude J, Santulli P, et al. Low birth weight is strongly associated with the risk of deep infiltrating endometriosis: results of a 743 case-control study. PLoS One. 2015; 10e0117387.
6. Vitonis AF, Baer HJ, Hankinson SE, et al. A prospective study of body size during childhood and early adulthood and the incidence of endometriosis. Hum Reprod. 2010; 25 (5): 1325–34. DOI: 10.1093/humrep/deq039
7. Ottolina J, Schimberni M, Makieva S, et al. Early-life factors, in-utero exposures and endometriosis risk: a meta-analysis. Reprod Biomed Online. 2020. DOI: 10.1016/j.rbmo.2020.04.005
8. Shafrir AL, Farland LV, Shah DK, et al. Risk for and consequences of endometriosis: A critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol. 2018; 51: 1–15. DOI: 10.1016/j.bpobgyn.2018.06.001
9. Farland Leslie V, Eliassen A Heather, Tamimi Rulla M, et al. History of breast feeding and risk of incident endometriosis: prospective cohort study. BMJ. 2017; 358: j3778.
10. Xie J, Kvaskoff M, Li Y, et al. Severe teenage acne and risk of endometriosis. Hum Reprod. 2014; 29 (11): 2592–9. DOI: 10.1093/humrep/deu207
11. Vercellini P, Buggio L, Somigliana E, et al. ‘Behind blue eyes’: the association between eye colour and deep infiltrating endometriosis. Hum Reprod. 2014; 29 (10): 2171–5. DOI: 10.1093/humrep/deu169
12. Missmer SA, Spiegelman D, Hankinson SE, et al. Natural hair color and the incidence of endometriosis. Fertil Steril. 2006; 85: 866–70.
13. Gynecology. National leadership. Ed. G.M. Savelyeva, G.T. Sukhikh, V.N. Serova et al. Moscow: GEOTAR-Media, 2017 (in Russian)
14. Koninckx PR, Ussia A, Adamyan L, et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019; 111 (2): 327–40. 
DOI: 10.1016/j.fertnstert.2018.10.013
15. Sampson JA. Metastatic or embolic endometriosis due to menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927; 3 (2): 93–110.
16. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927; 14 (2): 422–69.
17. Locci R, Nisolle M, Angioni S, et al. Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis. Reprod Biol Endocrinol. 2013; 11: 94. DOI: 10.1186/1477-7827-11-94
18. Cazacu E, Zota E, Margaritescu C, et al. Immunoexpression of matrix metalloproteinases MMP-1, MMP-2, MMP-9 and MMP-14 in extragenital endometriosis and eutopic endometrium. Mold Med J. 2020; 63 (4): 6–11. DOI: 10.5281/zenodo.4016800
19. Ζafrakas M, Κοtronis Κ, Papasozomenou P, et al. Extracellular matrix metalloproteinases in the etiopathogenesis of endometriosis: a systematic review and critical appraisal. Clin Exp Obstet Gynecol. 2020; 47 (2): 147–53.
20. Huang Y, Shen L, Cai A, Xiao J. Effect of warming Yang and removing blood stasis method on matrix metalloproteinases/tissue inhibitor metalloproteinases levels secreted by cultured endometrial cells from patients with endometriosis. J Tradit Chin Med. 2015; 35 (5): 571–6.
21. Lessey BA, Castelbaum AJ, Sawin SW, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metabol. 1994; 79: 643–9.
22. Shaco-Levy R, Sharabi S, Benharroch D, et al. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Eur J Obstet Gynecol Reprod Biol. 2008; 139: 226–32.
23. Matsuzaki S, Darcha C: Involvement of the Wnt/beta-catenin signaling pathway in the cellular and molecular mechanisms of fibrosis in endometriosis. PLoS One. 2013; 8:e76808.
24. Mnikhovich MV, Kakturskii  LV, Bezuglova TV, et al. Sravnitel’naia immunogistokhimicheskaia otsenka ekspressii E-kadgerina i β-katenina pri metastaticheskom i nemetastaticheskom rake molochnoi zhelezy nespetsificheskogo tipa. Opukholi zhenskoi reproduktivnoi sistemy. 2018; 14 (2): 14–20 (in Russian)
25. Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002; 17 (10): 2715–24. DOI: 10.1093/humrep/17.10.2715
26. Efanova NA, Mikhel’son AF, Lebedenko EIu, et al. Sovremennye aspekty patogeneza osnovnykh klinicheskikh proiavlenii i perspektiv terapii endometrioza. Tavricheskii mediko-biologicheskii vestnik. 2018; 21 (3) (in Russian)
27. Schulke L, Berbic M, Manconi F, et al. Dendritic cell populations in the eutopic and ectopic endometrium of women with endometriosis. Hum Reprod. 2009; 24 (7): 1695–703. DOI: 10.1093/humrep/dep071
28. Koninckx PR, Ussia A, Tahlak M, et al. Infection as a potential cofactor in the genetic-epigenetic pathophysiology of endometriosis: a systematic review. Facts Views Vis Obgyn. 2019; 11 (3): 209–16.
29. Hazzard TM, Molskness TA, Chaffin CL, Stouffer RL. Vascular endothelial growth factor (VEGF) and angiopoietin regulation by gonadotrophin and steroids in macaque granulosa cells during the peri-ovulatory interval. Mol Hum Reprod. 1999; 5: 1115–21.
30. Bourlev V, Volkov N, Pavlovitch S, et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006; 132: 501–9.
31. Orazov MR, Toktar LR. Bakterial’naia kontaminatsiia: novoe slovo v patogeneze endometrioza. Akusherstvo i ginekologiia. 2018; 3 (21). Available at: 
https://cyberleninka.ru/article/n/bakterialnaya-kontaminatsiya-novoe-slovo-v-patogeneze-endometrioza. Accessed: 22.12.2020 (in Russian)
32. Korotkova TD, Adamian LV, Stepanian AA, et al. Kletochnye i molekuliarnye faktory vrozhdennogo immuniteta v patogeneze naruzhnogo genital’nogo endometrioza u zhenshchin. Problemy reproduktsii. 2018; 24 (6): 22–31 (in Russian) DOI: 10.17116/repro20182406122 
33. Kalinitchenko SY. Vitamin D and women’s reproductive health. Problemi reprodukcii. 2016; 4: 28–36.
34. Evangelisti G, Barra F, Fichera M, Ferrero S. Vitamin D and endometriosis: Is there a correlation with disease severity? Clin Exp Reprod Med. 2020; 47 (3): 233–4. DOI: 10.5653/cerm.2019.03342
35. Orazov MR, Radzinskii VE, Khamoshina MB, et al. Vitamin D3 (kholekal’tsiferol) i tazovaia bol’, indutsirovannaia endometriozom iaichnikov. Trudnyi patsient. 2018; 16 (4): 34–9 (in Russian)
36. Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis. Fertil Steril 2017; 108 (6): 872–85.e1. DOI: 10.1016/j.fertnstert.2017.08.036
37. Pacchiarotti A, Caserta D, Sbracia M, Moscarini M. Expression of oct-4 and c-kit antigens in endometriosis. Fertil Steril. 2011; 95 (3): 1171–3. DOI: 10.1016/j.fertnstert.2010.10.029
38. Toullec L, Batteux F, Santulli P, et al. High Levels of Anti-GM-CSF Antibodies in Deep Infiltrating Endometriosis. Reprod Sci. 2020; 27 (1): 211–7. DOI: 10.1007/s43032-019-00021-8
39. Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril. 1991; 55 (4): 759–65.
40. Chapron C, Fauconnier A, Vieira M, et al. Anatomical distribution of deeply infiltrating endometriosis: surgical implications and proposition for a classification. Hum Reprod. 2003; 18 (1): 157–61.
41. Hoo W-L, Hardcastle R, Louden K. Management of endometriosis-related pelvic pain. Obstet Gynaecol. 2017; 19: 131–8. DOI: 10.1111/tog.12375
42. Vercellini P, Fedele G, Aimi G, et al. Association between endometriosis stage, lesion type, patient char-acteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients. Hum Reprod. 2007; 22 (1): 266–71.
43. Endometriosis: science and practice. Edited by L.C. Giudice, J.L.H. Evers, D.L. Healy. Blackwell Publishing Ltd, 2012; p. 82–3.
44. Carmignani L, Vercellini P, Spinelli M, et al. Pelvic endometriosis and hydroureteronephrosis. Fertil Steril. 2010; 93: 1741–4.
45. American Society for Reproductive Medicine. Endometriosis and infertility: A committee opinion. Fertil Steril. 2012; 98: 591–8.
46. Barinov SV, Lazareva OV, Ignat’ev IuT, et al. Aktual’nye voprosy diagnostiki glubokogo infil’trativnogo endometrioza. Mat’ i Ditia v Kuzbasse. 2020; 1 (80): 10–7  (in Russian) DOI: 10.24411/2686-7338-2020-10003
47. Chapron C, Lang JH, Leng JH, et al. Factors and regional differences associated with endometriosis: a multi-country, casecontrol study. Adv Ther. 2016; 33: 1385–407. DOI: 10.1007/s12325-016-0366-x
48. Matalliotakis I, Panidis D, Vlassis G, et al. Unexpected increase of the CA–19-9 tumor marker in patients with endometriosis. Eur J Gynaecol Oncol. 1998; 9: 498–500.
49. Fiala L, Bob P, Raboch J. Oncological markers CA–125, CA–19-9 and endometriosis. Medicine (Baltimore). 2018; 97 (51): 13759.
50. Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016; 4 (4): CD012165. DOI: 10.1002/14651858.CD012165
51. Alborzi S, Rasekhi A, Shomali Z, et al. Diagnostic accuracy of magnetic resonance imaging, transvaginal, and transrectal ultrasonographyin deep infiltrating endometriosis. Medicine (Baltimore). 2018; 97 (8): e9536. DOI: 10.1097/MD.0000000000009536
52. Zannoni L, Del Forno S, Coppola F, et al. Comparison of transvaginal sonography and computed tomography-colonography with contrast media and urographic phase for diagnosing deep infiltrating endometriosis of the posterior compartment of the pelvis: a pilot study. Jpn J Radiol. 2017; 35 (9): 546–54. DOI: 10.1007/s11604-017-0665-4
53. Chapron C, Vieira M, Chopin N, et al. Accuracy of rectal endoscopic ultrasonography and magnetic reso-nance imaging in the diagnosis of rectal involvement for patients presenting with deeply infiltrating endometriosis. J Ultrasound Obstet Gynecol. 2004; 24: 175–9.
54. Siegelman ES, Oliver ER. MR Imaging of Endometriosis: Ten Imaging Pearls. RadioGraphics. 2012; 32 (6): 1675–91.
55. Grasso RF, Di Giacomo V, Sedati P, et al. Diagnosis of deep infiltrating endometriosis: accuracy of magnetic resonance imaging and transvaginal 3D ultrasonography. Abdom Imaging. 2009; 19: 314.
56. Anaf V, El Nakadi I, De Moor V, et al. Anatomic significance of a positive barium enema in deep infiltrating endometriosis of the large bowel. World J Surg. 2009; 33: 822–7.
57. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005; 20 (10): 2698–704.
58. Klinicheskie rekomendatsii. Endometrioz. Minzdrav Rossii, 2020 (in Russian)
59. Sirintawat N, Sawang K, Chaiyasamut T, Wongsirichat N. Pain measurement in oral and maxillofacial surgery. J Dent Anesth Pain Med. 2017; 17 (4): 253–63. DOI: 10.17245/jdapm.2017.17.4.253
60. Nevropaticheskaia bol’: klinicheskie rekomendatsii po diagnostike i lecheniiu Rossiiskogo obshchestva po izucheniiu boli. Klinicheskie rekomendatsii №4. 2018  (in Russian) DOI: 10.25731/RASP.2018.04.025
61. Lai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in Endometriosis. Int J Biol Sci. 2019; 15 (13): 2783–97. DOI: 10.7150/ijbs.35128
62. Kuznetsova DE, Prokopenko SV, Makarenko TA, et al. Differentsirovannaia terapiia infil’trativnogo endometrioza i sindroma khronicheskoi tazovoi boli v zavisimosti ot vegetativnogo statusa patsientok. Problemy reproduktsii. 2018; 24 (6): 121–31 (in Russian) DOI: 10.17116/repro201824061121 
63. Slobodin TN, Maslova IG. Patogenez i sovremennyi kompleksnyi podkhod v lechenii bolevykh sindromov v nevrologii. Mezhdunar. nevrol. zhurn. 2018; 6 (100). Available at: https://cyberleninka.ru/article/n/patogenez-i-sovremennyy-kompleksnyy-podhod-v-lechenii-bolevyh-sind.... Accessed: 07.01.2021 (in Russian)
64. Aoki KR. Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A. Neurotoxicology. 2005; 26: 785–93. DOI: 10.1016/j.neuro.2005.01.017
65. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting: A review of the literature. Pain Practice. 2008; 8: 269–76. DOI: 10.1111/j.1533-2500.2008.00202.x
66. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004; 107: 125–33. DOI: 10.1016/j.pain.2003.10.008
67. Tandon HK, Stratton P, Sinaii N, et al. Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a painfocused treatment. Regional Anesthesia Pain Med. 2019; 44: 886–92. DOI: 10.1136/rapm-2019-100529
68. Del Forno S, Mabrouk M, Arena A, et al. Dienogest or norethindrone acetate for the treatment of ovarian endometriomas: can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019; 238: 120–4.
69. Caruso S, Iraci M, Cianci S, et al. Effects of long-term treatment with dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J Pain Res. 2019; 12: 2371–8.
70. Bayer. Visanne Post-approval Observational Study (VIPOS) [cited 2019 Nov]. Available at: https://clinicaltrials.bayer.com/study/20018
71. Bayer. To evaluate effectiveness of Visanne in improving quality of life in Asian women with Endometriosis [cited 2019 Nov]. Available at: https://clinicaltrials.bayer.com/study/2084
72. Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2mg dienogest/30 microg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 39 (8): 923–31.
73. Yamanaka A, Hada T, Matsumoto T, et al. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017; 216: 51–5.
74. Ebert AD, Dong L, Merz M, et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: The VISanne Study to Assess Safety in ADOlescents. J Pediatr Adolesc Gynecol. 2017; 30 (5): 560–7.
75. Seracchioli R, Mabrouk M, Manuzzi L, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom recurrence after conservative surgery for endometriosis. Hum Reprod. 2009; 24 (11): 2729–352.
76. Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008; 90 (5): 1583–8.
77. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015; 292 (3): 523–9.
DOI: 10.1007/s00404-015-3681-6

В.Е. Радзинский1, М.Р. Оразов*1, Л.М. Михалева2, М.А. Бекулова1

1 ФГАОУ ВО «Российский университет дружбы народов», Москва, Россия;
2 ФГБНУ «Научно-исследовательский институт морфологии человека», Москва, Россия
*omekan@mail.ru

________________________________________________

Viktor E. Radzinskii1, Mekan R. Orazov*1, Ljudmila M. Mihaleva2, Madina A. Bekulova1

1 People’s Friendship University of Russia, Moscow, Russia;
2 Research Institute of Human Morphology, Moscow, Russia
*omekan@mail.ru